Mdr tb
Reading File
Finding Sources
Searching PubMed
"multidrug-resistant tuberculosis"[MeSH Terms] AND treatment
Finding Sources
Searching PubMed
"MDR-TB" AND treatment
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive, up-to-date information from Harrison's 22E (2025), Goldman-Cecil, Murray & Nadel, Katzung, Tintinalli, and Goodman & Gilman. Here is the full structured answer:
Multidrug-Resistant Tuberculosis (MDR-TB)
Definition and Classification
MDR-TB is defined as M. tuberculosis resistant to at least isoniazid (INH) and rifampin (RIF) - the two most potent first-line bactericidal agents. Successive levels of resistance are recognized:
| Category | Definition |
|---|---|
| INH monoresistance | Resistant to INH only |
| MDR-TB | Resistant to INH + RIF |
| Pre-XDR-TB | MDR-TB + resistance to a fluoroquinolone OR a second-line injectable (intermediate step) |
| XDR-TB | MDR-TB + resistance to a fluoroquinolone + a second-line injectable (amikacin or streptomycin) |
Approximately 20% of M. tuberculosis isolates meet the MDR-TB definition. XDR-TB exists in regions including New York, California, Italy, Iran, and India and carries significantly higher mortality. - Tintinalli's Emergency Medicine
Mechanisms of Resistance
Drug resistance arises from spontaneous chromosomal point mutations (not transferable plasmids). Because there is no cross-resistance between drug classes, the probability of dual resistance equals the product of the individual mutation rates - which is why monotherapy invariably selects resistance:
| Drug | Gene mutated | Frequency |
|---|---|---|
| Rifampin | rpoB | ~95% of RIF resistance |
| Isoniazid | katG (main), inhA promoter | 50-95%; up to 45% |
| Pyrazinamide | pncA | up to 98% |
| Ethambutol | embB | 50-65% |
| Fluoroquinolones | gyrA-gyrB | 75-95% |
| Aminoglycosides | rrs gene | up to 80% |
- Harrison's Principles of Internal Medicine, 22E (2025)
Primary vs acquired resistance:
- Primary resistance: patient infected de novo with a resistant strain
- Acquired resistance: emerges during therapy (classically from inadequate regimens, monotherapy, poor-quality drugs, or non-compliance)
Epidemiology
- Highest burden in countries of the former Soviet Union and parts of Asia
- In the US, primary isoniazid resistance is stable at ~7-8%; primary MDR-TB has declined from 2.5% (1993) to <1% since 2000
- Global Map: Russia and Eastern Europe carry the darkest burden (see WHO Global Drug Resistance Surveillance data, Fig. 183-12 in Harrison's 22E)
Treatment Principles
Treatment requires combination therapy because any single drug selects for resistant mutants. Key principles:
- At least 2-3 drugs to which the organism is susceptible must always be co-administered
- Direct Observed Therapy (DOT) is essential
- Duration is markedly longer than drug-susceptible TB
- Drug susceptibility testing (DST) guides the regimen
Current WHO-Recommended MDR-TB Regimens (2024 Update)
The WHO issued updated guidance in 2024. Four approaches are now recognized:
1. BPaLM - 6-month, fully oral (preferred for new/less severe cases)
Bedaquiline + Pretomanid + Linezolid (600 mg) + Moxifloxacin
- The TB-PRACTECAL, Nix-TB, and ZeNix trials support this approach
- Fully oral, 6 months - a major advance over the prior 18-24 month regimens
2. BDLLfxCfz - 6-month oral alternative
Bedaquiline + Delamanid + Linezolid (600 mg) + Levofloxacin + Clofazimine
3. 9-month bedaquiline-containing oral regimens
- Multiple combinations assessed in STREAM stage 1 and endTB trials
- Different 9-month regimens tested (BLfx±M, LCfzD combinations)
4. Individualized longer regimen (≥18 months)
For complex or highly resistant cases - 5 active drugs in intensive phase, 4 in continuation phase, guided by the WHO priority grouping:
| WHO Group | Drugs |
|---|---|
| Group A (preferred) | Levofloxacin or moxifloxacin, Bedaquiline, Linezolid |
| Group B (add if needed) | Clofazimine, Cycloserine (or terizidone) |
| Group C (fallback) | Ethambutol, Delamanid, Pyrazinamide, Imipenem-cilastatin or meropenem + clavulanate, Amikacin (or streptomycin), Ethionamide (or prothionamide), p-aminosalicylic acid |
- Harrison's Principles of Internal Medicine, 22E (2025); Goldman-Cecil Medicine
Newer Drugs (Key Additions Since 2012)
Bedaquiline
- Diarylquinoline class; inhibits mycobacterial ATP synthase (novel mechanism)
- FDA-approved 2012 for MDR-TB; backbone of modern regimens
- Adverse effect: QT prolongation - ECG monitoring required
Pretomanid
- Bicyclic nitroimidazole; dual mechanism - inhibits mycolic acid synthesis (aerobic) and generates reactive nitrogen species (anaerobic/non-replicating bacilli)
- FDA-approved for XDR-TB in combination with bedaquiline + linezolid (BPaL)
- Dose: 200 mg/day
- Phase III efficacy established in Nix-TB and ZeNix trials
Delamanid
- Bicyclic nitroimidazole (like pretomanid); inhibits mycolic acid synthesis
- Licensed by EMA for MDR-TB
- Adverse effect: headache and QT prolongation (less than bedaquiline)
Linezolid
-
Oxazolidinone; inhibits bacterial protein synthesis (50S subunit)
-
Active against MDR and XDR strains; key component of BPaL/BPaLM
-
Adverse effects: peripheral neuropathy, bone marrow suppression (dose-limiting)
-
Goodman & Gilman's Pharmacological Basis of Therapeutics
Second-Line Drugs Used When Necessary
| Drug | Class | Notes |
|---|---|---|
| Levofloxacin / Moxifloxacin | Fluoroquinolones | Group A; cornerstone of most regimens |
| Clofazimine | Riminophenazine | Bactericidal; skin hyperpigmentation |
| Cycloserine | Cell wall inhibitor | Neuropsychiatric side effects |
| Kanamycin / Amikacin | Aminoglycosides | Injectable; ototoxicity/nephrotoxicity; most MDR strains remain amikacin-susceptible |
| Capreomycin | Polypeptide | Injectable; similar toxicities |
| Ethionamide | Thioamide | GI intolerance; hepatotoxicity |
| Imipenem + clavulanate | Carbapenem | Clavulanate is required to inhibit mycobacterial beta-lactamase |
Treatment Duration
- Shorter oral regimens (BPaLM / BDLLfxCfz): 6 months
- 9-month regimens: 9 months after negative culture conversion
- Longer individualized regimens: 18-24 months after sputum culture negativity
- Success rates with traditional 18-24 month regimens: rarely exceed 60% - Tintinalli
INH Monoresistance (Special Case)
When only INH resistance is confirmed (rifampin-susceptible):
- Regimen: Rifampin + Ethambutol + Pyrazinamide + Levofloxacin or Moxifloxacin for 6 months
- If fluoroquinolone contraindicated: RIF + EMB + PZA for 6 months
- Do not use this regimen until RIF resistance has been excluded (to avoid inadvertently treating unrecognized MDR-TB with an inadequate regimen) - Harrison's 22E; Goldman-Cecil
Surgery
Partial surgical resection is considered in selected patients with:
- Localized pulmonary MDR-TB
- Persistent positive cultures despite adequate medical therapy
- Refractory or cavitary disease
- Always done in conjunction with ongoing medical therapy
Special Populations
HIV co-infection: MDR-TB/HIV is particularly lethal. Drug-drug interactions between antiretrovirals and TB drugs (especially rifamycins) require expert management. Bedaquiline-based regimens avoid rifamycins and are therefore compatible with most ART regimens.
Pregnancy: MDR-TB in pregnancy (Creasy & Resnik) is a serious concern - some second-line drugs (aminoglycosides, ethionamide) are teratogenic; bedaquiline and pretomanid data in pregnancy remain limited. Expert consultation is mandatory.
Renal impairment: For CrCl <30 mL/min or hemodialysis - pyrazinamide and ethambutol require dose frequency reduction (3×/week); give after dialysis sessions. Aminoglycosides should be avoided or very carefully monitored. - Goldman-Cecil Medicine
Prevention of MDR-TB
- Sound combination therapy from the outset (never monotherapy)
- Fixed-dose combination tablets to prevent selective drug intake
- Direct observed therapy (DOT) for all intermittent regimens
- MDR-TB preventive therapy (TPT) for contacts of MDR-TB index cases - now endorsed in updated WHO guidance (Matteelli et al., 2025, Int J Infect Dis)
- Respiratory infection-control measures in healthcare settings
Recent Evidence (2024-2025)
- Recent advances in TB treatment (Motta et al., Clin Microbiol Infect, 2024) - reviews new drug developments and shorter regimen evidence
- Update on MDR-TB preventive therapy (Matteelli et al., Int J Infect Dis, 2025) - addresses TPT for contacts of MDR-TB cases toward global elimination
- WHO 2024 MDR-TB treatment guidelines confirmed BPaLM (6-month fully oral) as the new preferred standard for eligible patients
Sources: Harrison's Principles of Internal Medicine 22E (2025) | Goldman-Cecil Medicine | Tintinalli's Emergency Medicine | Murray & Nadel's Textbook of Respiratory Medicine | Goodman & Gilman's Pharmacological Basis of Therapeutics | Katzung's Basic and Clinical Pharmacology 16E
This is a shared conversation. Sign in to Orris to start your own chat.